The use of high-dose clopidogrel compared with use of standard-dose clopidogrel does not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis among patients with high on-treatment reactivity after percutaneous coronary intervention with drug-eluting stents, according to a recent multicenter study published in the Journal of the American Medical Association.
The use of high-dose clopidogrel compared with use of standard-dose clopidogrel does not reduce the incidence of death from cardiovascular causes, nonfatal myocardial infarction (MI), or stent thrombosis among patients with high on-treatment reactivity after percutaneous coronary intervention (PCI) with drug-eluting stents, according to a recent multicenter study published in the March 16, 2011, issue of the Journal of the American Medical Association.
Researchers compared high-dose clopidogrel (600-mg initial dose, 150-mg thereafter) with standard-dose clopidogrel (no additional loading dose, 75-mg daily) for 6 months in 2,214 patients participating in the Gauging Responsiveness with A VerifyNow assay -Impact on Thrombosis And Safety (GRAVITAS) study. The patients had high on-treatment reactivity 12 to 24 hours after PCI with drug-eluting stents.
At 6 months, 25 of 1,109 patients (2.3%) receiving high-dose clopidogrel compared with 25 of 1,105 patients (2.3%) receiving standard-dose clopidogrel died from cardiovascular causes, had a nonfatal MI, or had stent thrombosis. High-dose clopidogrel provided a 22% absolute reduction in the rate of high on-treatment reactivity at 30 days compared with standard-dose treatment. In addition, severe or moderate bleeding was not associated with the high-dose regimen.
"The results of GRAVITAS do not support a uniform treatment strategy of high-dose clopidogrel in patients with high on-treatment reactivity identified by a single platelet function test after PCI," concluded the researchers.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
March 25th 2024J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
FDA Issues Complete Response Letter for Onpattro in Heart Failure Indication
October 9th 2023Alnylam Pharmaceuticals will no longer pursue this indication of Onpattro and will instead on focus on a label expansion for Amvuttra, which is in phase 3 development to treat patients with cardiomyopathy of ATTR amyloidosis.